Pharma and biotech companies can't justify IPR opt outs, but you can see why they are asking for them
Register to access two of our subscriber only articles per month.
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Author | Editor-in-chief
@IAM_magazine One of the greats has left us. RIP. https://t.co/dFug4h3EYZ Read more
@IAM_magazine PARC's lawsuits against Facebook, Snap and Twitter could be a notable change in approach by innovation leader… https://t.co/Y300j9pF03 Read more
@IAM_magazine RT @EIP: Following an announcement to ban UK petrol & diesel car sales from 2030, EIP Partner Colin Lobban evaluates the implications for t… Read more
@IAM_magazine More evidence that patent validity is proving a significant hurdle for foreign licensors in China… https://t.co/W6ve922UEi Read more